Benefit of Eculizumab Compared to Standard of Care Still Unproven in C3 Glomerulopathy

Based on a retrospective evaluation of patients with C3 glomerulopathy, Le Quintrec et al1 conclude that eculizumab is of potential benefit in patients with rapidly progressive crescentic disease. A clear improvement in kidney function or reduction in urinary protein-creatinine ratio was observed in 12 of 26 patients. The majority of patients had received steroids, plasma exchange, or other immunosuppressants before eculizumab, which might suggest that eculizumab is more effective than standard therapy.

https://ift.tt/2D25yGT